Ra-SBRT is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients . J. Anal. Oncol. [Internet]. 2019 Nov. 29 [cited 2026 Apr. 17];8:71-6. Available from: https://www.neoplasiaresearch.com/index.php/jao/article/view/193